Hallmark Side Effect of Trodelvy (Sacituzumab Govitecan)
The hallmark adverse effect of Trodelvy is neutropenia, occurring in 51-83% of patients across clinical trials, with severe (grade 3-4) neutropenia developing in 32-53% of cases. 1
Primary Toxicity Profile
Neutropenia stands out as the most clinically significant adverse effect, consistently appearing as:
- The most common severe toxicity (grade 3-4) in pivotal trials
- The leading cause of treatment interruption (33-50% of patients) 1
- The most frequent reason for dose reduction (16-24% of patients) 1
The FDA drug label explicitly highlights neutropenia as requiring a boxed warning for severe neutropenia 1. In the landmark ASCENT trial, 51% of patients experienced severe neutropenia compared to 33% with standard chemotherapy 2. The TROPiCS-02 study showed even higher rates, with 83% experiencing decreased neutrophil counts and 53% having grade 3-4 neutropenia 1.
Secondary Hallmark: Diarrhea
Diarrhea represents the second hallmark toxicity, occurring in 54-62% of patients, with severe diarrhea in 10% 2. This is mechanistically related to the SN-38 payload (active metabolite of irinotecan) and occurs at significantly higher rates than standard chemotherapy (odds ratio 6.82) 3. The FDA label includes a boxed warning for severe diarrhea alongside neutropenia 1.
Complete Toxicity Spectrum
Beyond these hallmark effects, the most common adverse events include:
Hematologic (in order of frequency):
- Leukopenia (88-91% any grade; 10-38% grade 3-4)
- Anemia (51-93% any grade; 5-8% grade 3-4)
- Febrile neutropenia (6% in ASCENT) 2
Gastrointestinal:
- Nausea (59-62%)
- Vomiting (23-31%)
- Constipation (34%)
- Abdominal pain (20%) 1
Constitutional:
- Fatigue/asthenia (60-64%)
- Alopecia (48%) 1
Critical Clinical Pitfalls
UGT1A1 polymorphism significantly increases toxicity risk. Patients with UGT1A1*28 homozygosity have impaired metabolism of SN-38, leading to higher exposure and increased risk of neutropenia and diarrhea 4. The FDA label recommends avoiding concomitant UGT1A1 inhibitors 1.
Advanced age (≥65 years) represents an independent risk factor for severe adverse events, requiring closer monitoring 4.
Male sex, colitis, pneumonitis, febrile neutropenia, pyrexia, sepsis, and dehydration are risk factors for hospitalization (AUC 0.89 in predictive modeling) 5.
Management Imperatives
Real-world data demonstrates that G-CSF prophylaxis dramatically reduces neutropenia rates: only 25% of patients receiving any G-CSF prophylaxis developed any-grade neutropenia versus 44% without prophylaxis 6. Despite this, only 31% of real-world patients received G-CSF prophylaxis, while 59% required G-CSF at some point (including treatment) 6.
Most adverse events occur within 30 days of treatment initiation (>80%), with median onset at 6-7 days 5. This narrow window demands vigilant early monitoring.
Treatment discontinuation due to adverse events remains low (4-6%), indicating that with proper management, most toxicities are controllable 1, 7.